文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-PSMA-617放射性配体治疗用于mCRPC:VISION研究前的单中心分析

Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-02-16

这项回顾性单中心分析纳入78例有 first-line 化疗史的 mCRPC 患者,比较每周期6.0 GBq每8周(n=37)与7.5 GBq每6周(n=41)两种[177Lu]Lu-PSMA-617方案的疗效与安全性。两组>50% PSA下降率(35% vs 54%,p=0.065)、最佳PSA反应(-40.2% vs -57.8%,p=0.329)、中位估计生存(11.3 vs 12.7个月,p=0.384)及PSA-PFS(9.5 vs 12.3个月,p=0.258)均无显著差异,肾、肝、血液参数变化亦无显著差异。

要点

  • 6.0 GBq组与7.5 GBq组>50% PSA下降率分别为35%与54%,差异未达统计学显著(p=0.065)。
  • 两组中位估计生存11.3 vs 12.7个月(p=0.384),中位PSA-PFS 9.5 vs 12.3个月(p=0.258)。
  • 较高累积剂量耐受良好,未显著增加不良反应率;作者认为7.5 GBq每6周似乎更可取。

核心结论

  • 较高累积剂量的[177Lu]Lu-PSMA-617耐受良好,未显著增加不良反应发生率。
  • 7.5 GBq每6周方案的反应率略高但未达统计学显著,作者认为该方案似乎是更可取的治疗方案。
  • 作者指出未来研究需要阐明[177Lu]Lu-PSMA-617剂量相关疗效,以实现个体化医疗。

研究设计与样本

  • 回顾性分析,纳入78例有first-line化疗史的mCRPC连续患者。
  • 按每周期6.0 GBq[177Lu]Lu-PSMA-617治疗者37例,按每周期7.5 GBq治疗者41例。
  • 两组中位治疗间隔分别为8.4周(6.0 GBq组)与6.5周(7.5 GBq组)。
  • 评估并比较PSA反应、PSA-PFS、总生存及不良事件,采用卡方检验、Kaplan-Meier估计、Cox回归与log-rank检验;最佳PSA反应以Wilcoxon检验比较。

主要发现

  • >50% PSA下降率6.0 GBq组35% vs 7.5 GBq组54%,p=0.065,无显著差异。
  • 最佳PSA反应6.0 GBq组-40.2% vs 7.5 GBq组-57.8%,p=0.329,无显著差异。
  • 中位估计生存6.0 GBq组11.3个月 vs 7.5 GBq组12.7个月,p=0.384,无显著差异。
  • 中位PSA-PFS 6.0 GBq组9.5个月 vs 7.5 GBq组12.3个月,p=0.258,无显著差异。
  • 治疗期间肾脏、肝脏及血液细胞参数变化在两组间无显著差异。

临床怎么用

  • 作者认为7.5 GBq每6周方案反应率略高且未显著增加不良反应,似乎是更可取的治疗方案。
  • 作者指出未来研究需要阐明[177Lu]Lu-PSMA-617剂量相关疗效,以实现个体化医疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radioligand therapy with [177Lu]Lu-PSMA-617 is efficacious for the treatment of patients with metastasized castration-resistant prostate cancer (mCRPC). Various studies have evaluated the efficacy and safety of [177Lu]Lu-PSMA-617 using a dose of 6.0 GBq and an 8-week therapy interval. However, the first prospective phase III trial (VISION) plans to use an elevated cumulative dose by applying 7.5 GBq in a 6-week interval. The aim of the present study was to compare safety and efficacy of the two aforementioned [177Lu]Lu-PSMA-617 therapy regimes (7.5 GBq every 6 weeks vs. 6.0 GBq every 8 weeks). METHODS: A total number of 78 consecutive patients with mCRPC and a history of first-line chemotherapy were included in this retrospective analysis. The outcome of patients treated with 6.0 GBq [177Lu]Lu-PSMA-617 per cycle (n = 37) were compared with those treated with 7.5 GBq (n = 41) per cycle. The median therapy intervals were 8.4 weeks (6.0 GBq group) vs. 6.5 (7.5 GBq group). PSA response, PSA progression-free survival (PSA-PFS), overall survival, and adverse events were evaluated and compared between both groups. Chi-squared test, Kaplan Meier estimates, Cox regression, and log-rank test were used. The highest decline from pretherapeutic PSA levels was measured as percentage (best PSA response) and compared between groups by Wilcoxon test. RESULTS: There was no significant difference comparing the rate of > 50% PSA decline or best PSA response between the 6.0 GBq and 7.5 GBq group (35% vs. 54%, p = 0.065; and - 40.2% vs. - 57.8%, p = 0.329). The median estimated survival and PSA-PFS did not significantly differ between the 6.0 GBq and 7.5 GBq groups as well (11.3 vs. 12.7 months, p = 0.384; and 9.5 vs. 12.3 months, p = 0.258). There was no significant difference regarding the change of kidney, liver, and blood cell parameters under therapy between the treatment groups. CONCLUSION: Higher cumulated doses of [177Lu]Lu-PSMA-617 were well tolerated and caused no significantly increased rate of adverse reactions. Moreover, 7.5 GBq of [177Lu]Lu-PSMA-617 every 6 weeks causes slightly higher, though not statistically significant, response rates and seems therefore to be the preferable treatment regime. However, future studies are needed to elucidate the dose-related efficacy of [177Lu]Lu-PSMA-617 as a way to personalized medicine.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Seifert R, Kessel K, Schlack K, et al. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. Eur J Nucl Med Mol Imaging. 2020. PMID: 32062682. doi:10.1007/s00259-020-04703-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。